Last updated on January 2016

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

Brief description of study

This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with community-associated pneumonia (CAP)-related acute respiratory distress syndrome (ARDS). A third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. The patients will be followed for 28 days.

Clinical Study Identifier: NCT02595060

Contact Investigators or Research Sites near you

Start Over

Susanne Herold, MD, PhD

Universities of Marburg and Giessen Lung Center
Giessen, Germany
  Connect »